Therapy Class Overview Hepatitis C Virus Infection

Bharat Book Bureau provides the report, on “Therapy Class Overview Hepatitis C Virus Infection”. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.

https://www.bharatbook.com/healthcare-market-research-reports-347026/therapy-class-overview-hepatitis-c-virus-infection.html

23rd, April, 2016 - Mumbai, India: Bharatbook.com announces a report on “Therapy Class Overview Hepatitis C Virus Infection”. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria.

Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gilead’s Sofosbuvir / RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gilead’s Sofosbuvir / Ledipasvir (PhIII) and AbbVie / Enanta’s (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!

Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.

1.Executive Summary

2.Progress in the Clinical Development of HCV drugs

•Noteworthy progress in the Oral IFN –Free combinations for Treatment of HCV

•Options for the most...